Candel Therapeutics Inc (CADL)
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. Its pipeline includes CAN-2409, which is being evaluated in Phase 2a clinical trials for prostate cancer and non-small cell lung cancer, as well as CAN-3110, which is in Phase Ib clinical trials for recurrent high-grade glioma. The company is also advancing the enLIGHTEN Discovery Platform, a herpes simplex virus-based discovery system designed to use human biology and advanced analytics to identify new viral immunotherapy candidates for solid tumors. Formerly known as Advantagene, Inc., the company adopted its current name in November 2020. Candel Therapeutics was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CADL
|
$7.35
|
-28.0% Downside
|
Overvalued
|
$20.50
|
100.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-13.8x
|
5.4x
|
—
|
701.2 M
|
606.2 M
|
6.6%
|
77.5%
|
5.1
|
—
|
90.0%
|
